101 related articles for article (PubMed ID: 20359744)
1. Testicular cancer developed in a chronic myeloid leukemia patient with a continued complete cytogenetic and molecular response to imatinib. A case report and review of the literature.
Kata D; Mrówka-Kata K; Seweryn M; Pajak J; Najda J; Kyrcz-Krzemień S
Leuk Res; 2010 Sep; 34(9):e229-31. PubMed ID: 20359744
[No Abstract] [Full Text] [Related]
2. Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Roche-Lestienne C; Darré S; Laï JL; Facon T; Guilhot J; Preudhomme C
Haematologica; 2005 Jan; 90(1):131-3. PubMed ID: 15642682
[TBL] [Abstract][Full Text] [Related]
3. Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.
Kim HJ; Jung CW; Kim K; Ahn JS; Kim WS; Park K; Ko YH; Kang WK; Park K
J Clin Oncol; 2006 Aug; 24(24):4028-9. PubMed ID: 16921058
[No Abstract] [Full Text] [Related]
4. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
[TBL] [Abstract][Full Text] [Related]
5. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
6. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
7. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
Espinet B; Oliveira AC; Boqué C; Domingo A; Alonso E; Solé F
Haematologica; 2005 Apr; 90(4):556-8. PubMed ID: 15820956
[TBL] [Abstract][Full Text] [Related]
8. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
[TBL] [Abstract][Full Text] [Related]
9. Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma.
Breccia M; Martelli M; Cannella L; Russo E; Finolezzi E; Stefanizzi C; Levi A; Frustaci A; Alimena G
Leuk Res; 2008 Feb; 32(2):353-5. PubMed ID: 17825907
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.
Tsimberidou AM; Medina J; Cortes J; Rios A; Bonnie G; Faderl S; Kantarjian H; Garcia-Manero G
Leuk Res; 2004 Jun; 28(6):657-60. PubMed ID: 15120945
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
12. Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib.
Defina M; Gozzetti A; Rondoni M; Aprile L; Ippoliti M; Chitarrelli I; Lauria F; Bocchia M
Leuk Res; 2010 Aug; 34(8):e215-6. PubMed ID: 20334915
[No Abstract] [Full Text] [Related]
13. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
Kantarjian H; O'Brien S; Shan J; Huang X; Garcia-Manero G; Faderl S; Ravandi-Kashani F; Verstovsek S; Beth Rios M; Cortes J
Cancer; 2008 Feb; 112(4):837-45. PubMed ID: 18085610
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia in the imatinib era.
Druker BJ
Semin Hematol; 2003 Apr; 40(2 Suppl 2):1-3. PubMed ID: 12783367
[TBL] [Abstract][Full Text] [Related]
15. Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia.
Viniou NA; Vassilakopoulos TP; Giakoumi X; Mantzouranis M; Pangalis GA
Eur J Haematol; 2004 Jan; 72(1):58-60. PubMed ID: 14962264
[TBL] [Abstract][Full Text] [Related]
16. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
17. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
Press RD; Galderisi C; Yang R; Rempfer C; Willis SG; Mauro MJ; Druker BJ; Deininger MW
Clin Cancer Res; 2007 Oct; 13(20):6136-43. PubMed ID: 17947479
[TBL] [Abstract][Full Text] [Related]
18. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
Snyder DS; McMahon R; Cohen SR; Slovak ML
Am J Hematol; 2004 Feb; 75(2):92-5. PubMed ID: 14755375
[TBL] [Abstract][Full Text] [Related]
20. Imatinib alone and in combination for chronic myeloid leukemia.
Druker BJ
Semin Hematol; 2003 Jan; 40(1):50-8. PubMed ID: 12563611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]